Drugs / NNC109-0012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01282255 | Feb 2011 → Jan 2012 | rheumatoid arthritis | Novo Nordisk A/S | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC109-0012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01282255 ↗ |
| Action | Inhibit | “binds to and neutralizes the activity of interleukin-20” PMID 25749867 ↗ Mar 2015 |
| Modality | Monoclonal antibody | “a selective anti-IL-20 recombinant human monoclonal antibody (mAb)” PMID 25707477 ↗ Jun 2015 |
| Route | Subcutaneous | “administered subcutaneously (under the skin)” NCT01282255 ↗ |